Suchergebnisse - "tirzepatide"

Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.

Autoren: Hsu YH Liang YC Chan KC et al.

Quelle: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2025 Dec; Vol. 230, pp. 112995. Date of Electronic Publication: 2025 Nov 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE

MeSH-Schlagworte: Glucagon-Like Peptide-1 Receptor Agonists* , Osteoporosis*/epidemiology , Osteoporosis*/chemically induced , Diabetes Mellitus, Type 2*/drug therapy , Tirzepatide*/adverse effects , Tirzepatide*/therapeutic use , Hypoglycemic Agents*/adverse effects , Hypoglycemic Agents*/therapeutic use, Humans ; Retrospective Studies ; Female ; Male ; Middle Aged ; Aged ; Databases, Factual ; Risk Factors

Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.

Autoren: Wang JY Kang JW Peng TR et al.

Quelle: Clinical obesity [Clin Obes] 2025 Dec; Vol. 15 (6), pp. e70036. Date of Electronic Publication: 2025 Jul 21.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101560587 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1758-8111 (Electronic) Linking ISSN: 17588103 NLM ISO Abbreviation: Clin Obes Subsets: MEDLINE

MeSH-Schlagworte: Obesity*/drug therapy , Obesity*/complications , Tirzepatide*/therapeutic use , Tirzepatide*/adverse effects , Anti-Obesity Agents*/therapeutic use , Obesity Management*/methods, Humans ; Cardiometabolic Risk Factors ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications ; Randomized Controlled Trials as Topic ; Weight Loss/drug effects ; Adult ; Treatment Outcome

Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).

Autoren: Ng CD Divino V Wang J et al.

Quelle: Advances in therapy [Adv Ther] 2025 Nov; Vol. 42 (11), pp. 5468-5480. Date of Electronic Publication: 2025 Aug 28.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE

MeSH-Schlagworte: Glucagon-Like Peptides*/therapeutic use , Glucagon-Like Peptides*/administration & dosage , Weight Loss*/drug effects , Overweight*/drug therapy , Obesity*/drug therapy , Tirzepatide*/therapeutic use , Tirzepatide*/administration & dosage , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/administration & dosage , Gastric Inhibitory Polypeptide*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications ; Adult ; Aged ; Glucagon-Like Peptide-1 Receptor Agonists ; Glucagon-Like Peptide 1

Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.

Autoren: Guo L Dong X Ma J et al.

Quelle: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2025 Dec; Vol. 13 (12), pp. 1015-1029. Date of Electronic Publication: 2025 Oct 27.

Publikationsart: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III

Info zur Zeitschrift: Publisher: The Lancet, Diabetes & Endocrinology Country of Publication: England NLM ID: 101618821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-8595 (Electronic) Linking ISSN: 22138587 NLM ISO Abbreviation: Lancet Diabetes Endocrinol Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/drug therapy , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/administration & dosage , Tirzepatide*/therapeutic use , Tirzepatide*/administration & dosage , Tirzepatide*/adverse effects , Insulin Glargine*/therapeutic use , Insulin Glargine*/administration & dosage, Humans ; Male ; Female ; Double-Blind Method ; Middle Aged ; China/epidemiology ; Aged ; Drug Therapy, Combination ; Glycated Hemoglobin/analysis ; Treatment Outcome ; Adult ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Blood Glucose

Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.

Autoren: Gasoyan H Butsch WS Casacchia NJ et al.

Quelle: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2025 Dec; Vol. 33 (12), pp. 2296-2303. Date of Electronic Publication: 2025 Oct 02.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101264860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1930-739X (Electronic) Linking ISSN: 19307381 NLM ISO Abbreviation: Obesity (Silver Spring) Subsets: MEDLINE

MeSH-Schlagworte: Glucagon-Like Peptides*/therapeutic use , Glucagon-Like Peptides*/economics , Glucagon-Like Peptides*/administration & dosage , Glucagon-Like Peptides*/adverse effects , Obesity*/drug therapy , Tirzepatide*/therapeutic use , Tirzepatide*/economics , Tirzepatide*/administration & dosage , Tirzepatide*/adverse effects , Anti-Obesity Agents*/therapeutic use , Anti-Obesity Agents*/economics, Humans ; Male ; Female ; Middle Aged ; Cross-Sectional Studies ; Adult ; Aged ; Diabetes Mellitus, Type 2 ; Ohio ; Florida ; Electronic Health Records ; Glucagon-Like Peptide 1

Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.

Autoren: Lee BW Lee CB Lim S et al.

Quelle: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Dec; Vol. 27 (12), pp. 7110-7122. Date of Electronic Publication: 2025 Sep 15.

Publikationsart: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Tirzepatide*/therapeutic use , Tirzepatide*/adverse effects , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/adverse effects , Hypoglycemic Agents*/administration & dosage, Humans ; Female ; Male ; Middle Aged ; Republic of Korea/epidemiology ; Glycated Hemoglobin/analysis ; Glycated Hemoglobin/metabolism ; Aged ; Treatment Outcome ; Adult ; Body Weight/drug effects ; Hypoglycemia/chemically induced ; Blood Glucose/drug effects

Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.

Autoren: Ferch M Peitsch I Kautzky-Willer A et al.

Quelle: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2025 Nov 18; Vol. 110 (12), pp. 3364-3369.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE

MeSH-Schlagworte: Alstrom Syndrome*/drug therapy , Tirzepatide*/therapeutic use , Obesity*/drug therapy , Glucagon-Like Peptide-1 Receptor Agonists* , Gastric Inhibitory Polypeptide*/agonists, Humans ; Male ; Young Adult ; Adult ; Treatment Outcome ; Weight Loss/drug effects

Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.

Autoren: Kato S Kokita A Akanuma H et al.

Quelle: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2025 Nov; Vol. 229, pp. 112913. Date of Electronic Publication: 2025 Sep 20.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/diet therapy , Diabetes Mellitus, Type 2*/psychology , Diabetes Mellitus, Type 2*/blood , Hypoglycemic Agents*/therapeutic use , Patient Satisfaction* , Quality of Life* , Tirzepatide*/therapeutic use, Aged ; Female ; Humans ; Male ; Middle Aged ; Body Mass Index ; Cross-Sectional Studies ; Glycated Hemoglobin/metabolism ; Retrospective Studies

Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.

Autoren: Samuels JM Ye F Irlmeier R et al.

Quelle: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Nov; Vol. 27 (11), pp. 6200-6209. Date of Electronic Publication: 2025 Aug 05.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

MeSH-Schlagworte: Glucagon-Like Peptides*/therapeutic use , Glucagon-Like Peptides*/administration & dosage , Weight Loss*/drug effects , Obesity*/drug therapy , Tirzepatide*/therapeutic use , Tirzepatide*/administration & dosage , Glucagon-Like Peptide-1 Receptor Agonists* , Anti-Obesity Agents*/therapeutic use, Humans ; Middle Aged ; Female ; Male ; Adult ; Retrospective Studies ; Aged ; Young Adult ; Adolescent ; Academic Medical Centers ; Treatment Outcome ; Hypoglycemic Agents/therapeutic use ; Glucagon-Like Peptide 1

Tirzepatide for adults living with obesity.

Autoren: Franco JV Guo Y Varela LB et al.

Quelle: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2025 Oct 30; Vol. 10. Cochrane AN: CD016018. Date of Electronic Publication: 2025 Oct 30.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis; Review

Info zur Zeitschrift: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

MeSH-Schlagworte: Obesity*/drug therapy , Obesity*/complications , Tirzepatide*/therapeutic use , Tirzepatide*/adverse effects , Glucagon-Like Peptide-1 Receptor Agonists* , Anti-Obesity Agents*/therapeutic use , Anti-Obesity Agents*/adverse effects, Humans ; Randomized Controlled Trials as Topic ; Adult ; Quality of Life ; Bias ; Gastric Inhibitory Polypeptide/agonists

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.

Autoren: Krüger N Schneeweiss S Fuse K et al.

Quelle: JAMA [JAMA] 2025 Oct 14; Vol. 334 (14), pp. 1255-1266.

Publikationsart: Comparative Study; Journal Article; Observational Study

Info zur Zeitschrift: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

MeSH-Schlagworte: Heart Failure*/drug therapy , Heart Failure*/etiology , Heart Failure*/mortality , Heart Failure*/physiopathology , Tirzepatide*/administration & dosage , Tirzepatide*/adverse effects , Glucagon-Like Peptide-1 Receptor Agonists*/administration & dosage , Glucagon-Like Peptide-1 Receptor Agonists*/adverse effects , Glucagon-Like Peptide 1*/administration & dosage , Glucagon-Like Peptide 1*/adverse effects, Aged ; Female ; Humans ; Male ; Middle Aged ; Cohort Studies ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Hospitalization/statistics & numerical data ; Sitagliptin Phosphate/therapeutic use ; Sitagliptin Phosphate/adverse effects ; Stroke Volume/physiology ; Follow-Up Studies ; Obesity/complications ; Obesity/drug therapy ; Administrative Claims, Healthcare/statistics & numerical data

Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Autoren: Hannon TS Chao LC Barrientos-Pérez M et al.

Quelle: Lancet (London, England) [Lancet] 2025 Oct 04; Vol. 406 (10511), pp. 1484-1496. Date of Electronic Publication: 2025 Sep 17.

Publikationsart: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/adverse effects , Hypoglycemic Agents*/administration & dosage , Tirzepatide*/adverse effects , Tirzepatide*/therapeutic use , Gastric Inhibitory Polypeptide*/therapeutic use , Gastric Inhibitory Polypeptide*/administration & dosage , Gastric Inhibitory Polypeptide*/adverse effects, Humans ; Adolescent ; Double-Blind Method ; Child ; Male ; Female ; Treatment Outcome ; Glycated Hemoglobin/analysis ; Blood Glucose/drug effects ; Metformin/therapeutic use

Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.

Autoren: He YM Zeng C Zhang YF et al.

Quelle: Diabetes/metabolism research and reviews [Diabetes Metab Res Rev] 2025 Oct; Vol. 41 (7), pp. e70097.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883450 Publication Model: Print Cited Medium: Internet ISSN: 1520-7560 (Electronic) Linking ISSN: 15207552 NLM ISO Abbreviation: Diabetes Metab Res Rev Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/drug therapy , Heart Failure*/drug therapy , Heart Failure*/etiology , Heart Failure*/prevention & control , Heart Failure*/pathology , Obesity*/complications , Tirzepatide*/therapeutic use, Humans ; Randomized Controlled Trials as Topic ; Prognosis ; Hypoglycemic Agents/therapeutic use

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.

Autoren: Sattar N García-Pérez LE Rodríguez A et al.

Quelle: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Oct; Vol. 27 (10), pp. 5386-5392. Date of Electronic Publication: 2025 Jun 24.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

MeSH-Schlagworte: Obesity*/drug therapy , Obesity*/complications , Obesity*/metabolism , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications , Cardiovascular Diseases*/prevention & control , Cardiovascular Diseases*/epidemiology , Tirzepatide*/therapeutic use , Hypoglycemic Agents*/therapeutic use , Gastric Inhibitory Polypeptide*/therapeutic use, Humans ; Glucagon-Like Peptide-1 Receptor Agonists

HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.

Autoren: Vilsbøll T Malecki MT Sharma P et al.

Quelle: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Oct; Vol. 27 (10), pp. 5498-5505. Date of Electronic Publication: 2025 Jul 31.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Diabetes Mellitus, Type 2*/complications , Glycated Hemoglobin*/analysis , Glycated Hemoglobin*/metabolism , Glycated Hemoglobin*/drug effects , Hypoglycemic Agents*/therapeutic use , Tirzepatide*/therapeutic use , Weight Loss*/drug effects, Aged ; Female ; Humans ; Male ; Middle Aged ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Gastric Inhibitory Polypeptide ; Glucagon-Like Peptide-1 Receptor Agonists ; Glucagon-Like Peptides/therapeutic use ; Treatment Outcome ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic ; Glucagon-Like Peptide 1

Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.

Autoren: Cerchi E Santo PADE de Oliveira MC et al.

Quelle: International journal of obesity (2005) [Int J Obes (Lond)] 2025 Dec; Vol. 49 (12), pp. 2415-2425. Date of Electronic Publication: 2025 Sep 27.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis

Info zur Zeitschrift: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101256108 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5497 (Electronic) Linking ISSN: 03070565 NLM ISO Abbreviation: Int J Obes (Lond) Subsets: MEDLINE

MeSH-Schlagworte: Weight Loss*/drug effects , Obesity*/drug therapy , Obesity*/complications , Tirzepatide*/therapeutic use , Anti-Obesity Agents*/therapeutic use , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications, Humans ; Randomized Controlled Trials as Topic

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.

Autoren: Bhatnagar P Ahmad NN Li X et al.

Quelle: Nature medicine [Nat Med] 2025 Oct; Vol. 31 (10), pp. 3294-3296. Date of Electronic Publication: 2025 Aug 26.

Publikationsart: Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

MeSH-Schlagworte: Receptor, Melanocortin, Type 4*/genetics , Receptor, Melanocortin, Type 4*/deficiency , Weight Loss*/drug effects , Weight Loss*/genetics , Obesity*/drug therapy , Obesity*/genetics , Tirzepatide*/therapeutic use, Humans ; Male ; Female ; Adult ; Mutation/genetics ; Middle Aged ; Body Mass Index ; Receptors, Gastrointestinal Hormone/agonists

Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.

Autoren: Pearson ER Del Prato S Pavo I et al.

Quelle: Diabetes [Diabetes] 2025 Oct 01; Vol. 74 (10), pp. 1850-1862.

Publikationsart: Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE

MeSH-Schlagworte: Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Diabetes Mellitus, Type 2*/metabolism , Hypoglycemic Agents*/therapeutic use , Blood Glucose*/drug effects , Blood Glucose*/metabolism , Tirzepatide*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Glycated Hemoglobin/metabolism ; Aged ; Weight Loss/drug effects ; Body Weight/drug effects ; Glycemic Control

Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.

Autoren: Al Ozairi E Irshad M Alkandari J et al.

Quelle: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Jan; Vol. 28 (1), pp. 166-173. Date of Electronic Publication: 2025 Oct 06.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

MeSH-Schlagworte: Liraglutide*/therapeutic use , Liraglutide*/adverse effects , Glucagon-Like Peptides*/therapeutic use , Glucagon-Like Peptides*/adverse effects , Diabetes Mellitus, Type 1*/drug therapy , Diabetes Mellitus, Type 1*/complications , Diabetes Mellitus, Type 1*/blood , Hypoglycemic Agents*/therapeutic use , Weight Loss*/drug effects , Tirzepatide*/therapeutic use , Obesity*/drug therapy , Obesity*/complications, Humans ; Female ; Male ; Adult ; Middle Aged ; Glycated Hemoglobin/analysis ; Treatment Outcome ; Body Mass Index ; Blood Glucose ; Glucagon-Like Peptide 1

Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.

Autoren: Shukla AP Dunn JP Gomez Valderas E et al.

Quelle: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Jan; Vol. 28 (1), pp. 452-462. Date of Electronic Publication: 2025 Nov 04.

Publikationsart: Journal Article; Randomized Controlled Trial; Comparative Study

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

MeSH-Schlagworte: Quality of Life* , Glucagon-Like Peptides*/therapeutic use , Obesity*/drug therapy , Obesity*/psychology , Overweight*/drug therapy , Overweight*/psychology , Tirzepatide*/therapeutic use , Hypoglycemic Agents*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Adult ; Treatment Outcome ; Weight Loss/drug effects ; Glucagon-Like Peptide 1